Skip to contentG
Guided Therapeutics Inc
G
GTHPGuided Therapeutics Inc Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$16.00K$16.00Kderived−62.8% vs Q4 2018 Net Income$1.08M$1.08MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$12,000N/M Operating Incomederived-$165,000N/M Operating Cash Flowderived-$204,000N/M Free Cash Flowderived-$204,000— Margins · derivedGross margin75.0%+172.7 pt vs Q4 2018
Operating margin-1031.3%+8.3 pt vs Q4 2018
Net margin6768.8%+13140.8 pt vs Q4 2018
ended Dec 31, 2019 · filed Apr 20, 2020 · 111 d after period end